Bioceltix SA

As of March 31, 2026, Bioceltix SA carries a market capitalization of 422.66M, placing it among publicly traded companies globally. Its enterprise value stands at 362.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bioceltix SA's next confirmed earnings release is scheduled for November 27, 2026.

As of March 31, 2026, Bioceltix SA has 5.53M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Bioceltix SA maintains a current ratio of 22.56, meaning it holds 22.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.35, indicating conservative leverage, while an interest coverage ratio of -140.79 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Bioceltix SA posted a negative return on equity (ROE) of -33.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.27, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 41.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2026, Bioceltix SA recorded an income tax benefit of -41,289.41 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -17.23M and -17.18M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Bioceltix SA's stock has declined approximately 35.57% over the past 52 weeks. The 50-day moving average sits at 74.84, while the 200-day moving average is 81.84.

Over the twelve months ended March 31, 2026, Bioceltix SA generated - - in revenue and converted that into -17.18M in net income, yielding earnings per share of -3.33. EBITDA reached -16.67M, while operating income came in at -17.33M.

As of March 31, 2026, Bioceltix SA holds 60.79M in cash and equivalents against 235,301.34 in total debt, resulting in a net debt position of -60.79M. Total book value stands at 67.59M, with working capital of 62.20M providing operational flexibility.

Bioceltix SA produced -17.56M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -3.15M in capital expenditures, free cash flow totaled -20.71M - equivalent to -4.01 per share.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -5.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.58, meaning Bioceltix SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, Bioceltix SA has an Altman Z-Score of 83.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.